6-K

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

450, 5th Street

Washington, D.C. 20549

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of December, 2005.

Daiichi Sankyo Company, Limited

(Translation of registrant’s name into English)

5-1, Nihonbashi 3-chome

Chuo-ku, Tokyo 103-8426

Japan

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  þ            Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes  ¨            No  þ

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes  ¨            No  þ

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨            No  þ

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DAIICHI SANKYO COMPANY, LIMITED
DATE: December 14, 2005	By:	/s/ Takashi Shoda
	Name:	Takashi Shoda
	Title:	President and Representative Director

EXHIBIT INDEX

Exhibit Number		Description of Exhibit
99.1	—	Press Release: “Transfer of a Portion of Sankyo Pharma GmbH Products”

EX-99.1

Exhibit 99.1

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Takashi Shoda, President and Representative Director

(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)

Please address inquiries to Toshio Takahashi, Corporate Officer in Charge,

Corporate Communications Department

Telephone: +81-3-6225-1126

Transfer of a Portion of Sankyo Pharma GmbH Products

Tokyo, December 14, 2005 – DAIICHI SANKYO COMPANY, LIMITED announced today that Sankyo Pharma GmbH (headquartered in Munich, Germany; hereafter, SPG) - a European subsidiary of Sankyo Co., Ltd. (President: Yasuhiro Ikegami; hereafter, Sankyo), a wholly owned subsidiary of DAIICHI SANKYO COMPANY, LIMITED - has agreed to cede a total of 11 products sold in Europe including the endermic antiphlogistic Mobilat®, and the circulatory enhancer and humectant Hirudoid®, among others to STADA Arzneimittel AG (headquartered in Bad Vilbel, Germany).

In 1990, Sankyo purchased capital interest in Luitpold Werk, the forerunner of SPG, and in 1991, Luitpold Werk became a wholly owned subsidiary of Sankyo. The list of pharmaceuticals in question are products which were sold by the former Luitpold Werk and are still being sold today. In the future, SPG will focus on ethical drugs such as the antihypertensive Olmetec® (generic name: olmesartan medoxomil), and will proceed to develop this business in Europe.

<STADA Arzneimittel AG company overview>

• Headquarters: Bad Vilbel, Germany

• Established: 1895

• Main business: Started in the generic drugs business in 1975, which has since become the company’s core business.

• Number of employees: Approximately 1400.